The elevated FcRn affinity strategy is used by the anti-IL6R antibody, tocilizumab, which has been shown to reduce tumor growth in mice with pancreatic ductal adenocarcinoma [13,14]. The gene discussed is FCGRT; the disease is neoplasm.